{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:02:25Z","timestamp":1789794145355,"version":"4.0.1"},"reference-count":64,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/bst.2026.01148","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T22:11:02Z","timestamp":1787263862000},"page":"398-411","source":"Crossref","is-referenced-by-count":0,"title":["Immunometabolic reprogramming &lt;i&gt;via&lt;\/i&gt; GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework"],"prefix":"10.5582","volume":"20","author":[{"given":"Liqin","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."},{"name":"Research Institute of the McGill University Health Centre, Montr\u00e9al, QC, Canada."},{"name":"Chronic Viral Illness Service, McGill University Health Centre, Montr\u00e9al, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Isnard","sequence":"first","affiliation":[{"name":"Research Institute of the McGill University Health Centre, Montr\u00e9al, QC, Canada."},{"name":"Chronic Viral Illness Service, McGill University Health Centre, Montr\u00e9al, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, The Ninth People&apos;s Hospital of Dongguan, Dongguan, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"first","affiliation":[{"name":"School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"He","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Shenzhen Third People&apos;s Hospital, Shenzhen, Guangdong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre, Montr\u00e9al, QC, Canada."},{"name":"Chronic Viral Illness Service, McGill University Health Centre, Montr\u00e9al, QC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Marcus JL, Leyden WA, Alexeeff SE, Anderson AN, Hechter RC, Hu H, Lam JO, Towner WJ, Yuan Q, Horberg MA, Silverberg MJ. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw Open. 2020; 3:e207954.","DOI":"10.1001\/jamanetworkopen.2020.7954"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bares SH, Smeaton LM, Xu A, Godfrey C, McComsey GA. HIV-Infected Women Gain More Weight than HIV-Infected Men Following the Initiation of Antiretroviral Therapy. J Womens Health (Larchmt). 2018; 27:1162-1169.","DOI":"10.1089\/jwh.2017.6717"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sax PE, Erlandson KM, Lake JE, <i>et al<\/i>. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020; 71:1379-1389.","DOI":"10.1093\/cid\/ciz999"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wohl DA, Koethe JR, Sax PE, McComsey GA, Kuritzkes DR, Moyle G, Kaplan L, van Wyk J, Campo RE, Cohen C. Antiretrovirals and Weight Change: Weighing the Evidence. Clin Infect Dis. 2024; 79:999-1005.","DOI":"10.1093\/cid\/ciae191"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bares SH, Wu X, Tassiopoulos K, Lake JE, Koletar SL, Kalayjian R, Erlandson KM. Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease. Clin Infect Dis. 2024; 78:395-401.","DOI":"10.1093\/cid\/ciad545"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shah ASV, Stelzle D, Lee KK, <i>et al<\/i>. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. Circulation. 2018; 138:1100-1112.","DOI":"10.1161\/CIRCULATIONAHA.117.033369"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ndumele CE, Rangaswami J , Chow SL, <i>et a l<\/i> . Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023; 148:1606-1635.","DOI":"10.1161\/CIR.0000000000001184"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Liu C, Sun L, Xiao X, He Y, Zhao F, Luo Y, Zhao D, Jiang Y, Gao K, Gong W, Li X, Kong T, Lu H, Liu J. Longitudinal evolution and risk profiles of comorbidity among people with HIV in China: a retrospective cohort study. Front Public Health. 2025; 13:1753514.","DOI":"10.3389\/fpubh.2025.1753514"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384:989-1002.","DOI":"10.1056\/NEJMoa2032183"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026; 32:47-57.","DOI":"10.1038\/s41591-025-04124-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387:205-216.","DOI":"10.1056\/NEJMoa2206038"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lincoff AM, Brown-Frandsen K, Colhoun HM, <i>et al<\/i>. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023; 389:2221-2232.","DOI":"10.1056\/NEJMoa2307563"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024; 391:109-121.","DOI":"10.1056\/NEJMoa2403347"},{"key":"14","unstructured":"14. Thomas TS, Srinivasa S. Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV. Top Antivir Med. 2024; 32:579-588."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Haidar L, Delaney JAC. Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications. Curr Opin HIV AIDS. 2026; 21:355-361.","DOI":"10.1097\/COH.0000000000001059"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Eckard AR, Wu Q, Sattar A, Ansari-Gilani K, Labbato D, Foster T, Fletcher AA, Adekunle RO, McComsey GA. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Lancet Diabetes Endocrinol. 2024; 12:523-534.","DOI":"10.1016\/S2213-8587(24)00150-5"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lake JE, Kitch DW, Kantor A, Muthupillai R, Klingman KL, Vernon C, Belaunzaran-Zamudio PF, Fichtenbaum CJ, Heath S, Perazzo H, Corey K, Brown TT, Landay A, Sattler F, Erlandson KM. The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV. Ann Intern Med. 2024; 177:835-838.","DOI":"10.7326\/M23-3354"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Haidar L, Crane HM, Nance RM, <i>et al<\/i>. Weight loss associated with semaglutide treatment among people with HIV. AIDS. 2024; 38:531-535.","DOI":"10.1097\/QAD.0000000000003791"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Su QJ, Ashenhurst JR, Xu W, Tran V, Ryanne Wu R, Weldon CH, Shi J, Hicks B, 23andMe Research Team, Abul-Husn NS, Aslibekyan S, Holmes MV, Koelsch BL, Auton A. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026; 653:770-775.","DOI":"10.1038\/s41586-026-10330-z"},{"key":"20","unstructured":"20. Marin M, Mfusi S, Gopee K, <i>et al<\/i>. GLP-1 RA Induces Gut T-Cell and Epithelial Remodeling in PWH From a Clinical Trial in South Africa. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2026; Abstract 115."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Corley MJ, Dwaraka VB, Pang AP, Labbato D, Smith R, Ross Eckard A, McComsey GA. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun. 2026; 17:6606.","DOI":"10.1038\/s41467-026-72861-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Crawford PA, Rhein J, Chipman JG, <i>et al<\/i>. Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection. bioRxiv [Preprint]. 2026:2026.01.09.698696. doi: 10.64898\/2026.01.09.698696.","DOI":"10.64898\/2026.01.09.698696"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Koethe JR, Jenkins CA, Lau B, <i>et al<\/i>. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016; 32:50-8.","DOI":"10.1089\/aid.2015.0147"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, Koethe JR, Sterling TR. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2020; 70:1267-1274.","DOI":"10.1093\/cid\/ciz407"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Li T, Sun L, He Y, Zhou Y, Xu L, Zhao F, Hu D, Wang H, Lu H, Liu J. Increasing trends of overweight and obesity in treatment-naive people living with HIV in Shenzhen from 2014 to 2020: an emerging health concern. Front Public Health. 2023; 11:1186838.","DOI":"10.3389\/fpubh.2023.1186838"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sun L, Jiang Y, Isnard S, <i>et al<\/i>. Comparative safety and efficacy of BIC\/FTC\/TAF versus DTG+3TC in antiretroviral treatment-naive patients with HIV as first-line regimens: A real-world cohort study. Biosci Trends. 2026; 20:205-216.","DOI":"10.5582\/bst.2025.01335"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hawkins KL, Zhang L, Ng DK, Althoff KN, Palella FJ Jr, Kingsley LA, Jacobson LP, Margolick JB, Lake JE, Brown TT, Erlandson KM. Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. AIDS. 2018; 32:1257-1266.","DOI":"10.1097\/QAD.0000000000001829"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020; 6:48.","DOI":"10.1038\/s41572-020-0181-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gorwood J, Bourgeois C, Pourcher V, <i>et al<\/i>. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human\/Simian Adipose Tissue and Human Adipocytes. Clin Infect Dis. 2020; 71:e549-e560.","DOI":"10.1093\/cid\/ciaa259"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Nguyen Q, Wooten D, Lee D, Moreno M, Promer K, Rajagopal A, Tan M, Tang M, Duren K, Yin J, Hill L. Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV. Clin Infect Dis. 2024; 79:978-982.","DOI":"10.1093\/cid\/ciae151"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Beach R, Tims-Cook Z, McGary CS, Thote T. Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists. Clin Infect Dis. 2026; 82:S87-S91.","DOI":"10.1093\/cid\/ciag121"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Pryke L, Koethe JR, Bailin S. Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments. Curr HIV\/AIDS Rep. 2026; 23:6.","DOI":"10.1007\/s11904-026-00776-1"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Ma J, Ruderman SA, Haidar L, <i>et al<\/i>. Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort. AIDS. 2026; doi: 10.1097\/QAD.0000000000004544.","DOI":"10.1097\/QAD.0000000000004544"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Noe S, Ivanova A, Johnsson-Oldenb\u00fcttel C, Sch\u00e4fer G, Schewe K, Hoffmann C. Immunological alterations with GLP-1 agonists in people living with HIV. HIV Med. 2024; 25:893-894.","DOI":"10.1111\/hiv.13631"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, Routy JP. Circulating LPS and (1\u21923)-\u03b2-D-Glucan: A Folie \u00e0 Deux Contributing to HIV-Associated Immune Activation. Front Immunol. 2019; 10:465.","DOI":"10.3389\/fimmu.2019.00465"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Ouyang J, Yan J, Zhou X, Isnard S, Harypursat V, Cui H, Routy JP, Chen Y. Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV. Front Immunol. 2023; 14:1173956.","DOI":"10.3389\/fimmu.2023.1173956"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Isnard S, Lin J, Fombuena B, <i>et al<\/i>. Repurposing Metformin in Nondiabetic People With HIV: Influence on Weight and Gut Microbiota. Open Forum Infect Dis. 2020; 7:ofaa338.","DOI":"10.1093\/ofid\/ofaa338"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Funderburg NT, Ross Eckard A, Wu Q, Sattar A, Ailstock K, Cummings M, Labbato D, McComsey GA. The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy. Open Forum Infect Dis. 2025; 12:ofaf152.","DOI":"10.1093\/ofid\/ofaf152"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sasaki T, Giang SM, Wu J, Yokoo T, Gallagher M, Bellomo R, Wang AY. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2026; 41:681-691.","DOI":"10.1093\/ndt\/gfaf193"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, <i>et al<\/i>. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023; 389:1069-1084.","DOI":"10.1056\/NEJMc2312296"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA, SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025; 392:427-437.","DOI":"10.1056\/NEJMoa2410027"},{"key":"42","unstructured":"42. Ross Eckard A, Wu Q, Sattar A, Labbato D, Koberssy Z, Daher J, McComsey GA. Effects of semaglutide on subclinical cardiovascular health in people with HIV. In: Conference on Retroviruses and Opportunistic Infections (CROI); 2026; Abstract 699."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kim HH, Dixit VD. Metabolic regulation of immunological aging. Nat Aging. 2025; 5:1425-1440.","DOI":"10.1038\/s43587-025-00921-2"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br J Pharmacol. 2022; 179:625-641.","DOI":"10.1111\/bph.15677"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Ruderman SA, Crane HM, Haidar L, <i>et al<\/i>. Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV. AIDS. 2026; doi: 10.1097\/QAD.0000000000004596.","DOI":"10.1097\/QAD.0000000000004596"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024; 15:4548.","DOI":"10.1038\/s41467-024-48780-6"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Planas D, Pagliuzza A, Ponte R, <i>et al<\/i>. LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine. 2021; 65:103270.","DOI":"10.1016\/j.ebiom.2021.103270"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Ben Nasr M, Usuelli V, Dellepiane S, <i>et al<\/i>. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 2024; 36:1302-1319.e12.","DOI":"10.1016\/j.cmet.2024.05.001"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Ghahari N, Telittchenko R, Loucif H, Isnard S, Routy JP, Olagnier D, van Grevenynghe J. Harnessing Autophagy to Overcome Antigen-Specific T-Cell Dysfunction: Implication for People Living with HIV-1. Int J Mol Sci. 2023; 24:11018.","DOI":"10.3390\/ijms241311018"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Isnard S, Royston L, Berini CA, <i>et al<\/i>. Plasma GDF-15 levels are associated with HIV reservoir markers independently of inflammation in people with HIV on antiretroviral therapy. J Infect Dis. 2026; jiag202.","DOI":"10.1093\/infdis\/jiag202"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Sierra L, Aitharaju V, Prado R, Cymbal M, Chaterjee A, Khurana A, Patel R, Firkins S, Simons-Linares R. In-Hospital Outcomes of Bariatric Surgery in People Living with HIV: A Nationwide Analysis. Obes Surg. 2025; 35:3111-3119.","DOI":"10.1007\/s11695-025-08007-z"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Aitharaju V, Sierra L, Syed A, Flora B, Staneff E, Chatterjee A, Khurana A, Patel R, Firkins S, Simons-Linares R. Safety of bariatric surgery in HIV-positive patients on antiretroviral therapy. Surg Obes Relat Dis. 2025; 21:1126-1130.","DOI":"10.1016\/j.soard.2025.06.004"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Zino L, Kingma JS, Marzolini C, Richel O, Burger DM, Colbers A. Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV. Clin Pharmacokinet. 2022; 61:619-635.","DOI":"10.1007\/s40262-022-01120-7"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Patoulias D, Karakasis P, Ru\u017ea I, El-Tanani M, Rizzo M. Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities. Expert Opin Drug Saf. 2025; 24:121-124.","DOI":"10.1080\/14740338.2024.2435426"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Vilsb\u00f8ll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Heged\u00fcs L. Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. Diabetes Obes Metab. 2026; 28:1499-1507.","DOI":"10.1111\/dom.70291"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Brito JP, Herrin J, Swarna KS, Singh Ospina NM, Montori VM, Toro-Tobon D, Umpierrez GE, Galindo RJ, Deng Y, Mickelson MM, Shao H, Polley EC, McCoy RG. GLP-1RA Use and Thyroid Cancer Risk. JAMA Otolaryngol Head Neck Surg. 2025; 151:243-252.","DOI":"10.1001\/jamaoto.2024.4852"},{"key":"57","unstructured":"57. U.S. Food and Drug Administration. WEGOVY (semaglutide) prescribing information. Revised May 2026. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215256s031lbl218316s003lbl.pdf<\/i> (accessed August 10, 2026)."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026; 392:e085304.","DOI":"10.1136\/bmj-2025-085304"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Erlandson KM, Kitch DW, Kantor A, Belaunzaran-Zamudio PF, Brown TT, Fichtenbaum CJ, Heath SL, Sattler FR, Lake JE. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clin Infect Dis. 2026; 82:e544-e548.","DOI":"10.1093\/cid\/ciaf652"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD. Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication. JAMA Health Forum. 2025; 6:e254258.","DOI":"10.1001\/jamahealthforum.2025.4258"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Takata H, Mitchell JL, Pacheco J, <i>et al<\/i>. An active HIV reservoir during ART is associated with maintenance of HIV-specific CD8+ T cell magnitude and short-lived differentiation status. Cell Host Microbe. 2023; 31:1494-1506.e4.","DOI":"10.1016\/j.chom.2023.08.012"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Dub\u00e9 M, Tastet O, Dufour C, Sannier G, Brassard N, Delgado GG, Pagliuzza A, Richard C, Nayrac M, Routy JP, Prat A, Estes JD, Fromentin R, Chomont N, Kaufmann DE. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. Cell Host Microbe. 2023; 31:1507-1522.e5.","DOI":"10.1016\/j.chom.2023.08.006"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Sise ME, Katz-Agranov N, Strohbehn IA, Harden D, Moreno D, Durbin C, Toribio M, Neilan TG, Zanni MV. Brief Report: Use and Side Effects of Sodium-Glucose Transporter 2 Inhibitors Among US People With HIV With Clinical Indications. J Acquir Immune Defic Syndr. 2023; 94:53-56.","DOI":"10.1097\/QAI.0000000000003227"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008; 22:1719-1728.","DOI":"10.1097\/QAD.0b013e32830a5058"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01148\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:29:46Z","timestamp":1789792186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/20\/4\/20_2026.01148\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01148","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01148"}}